top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Fouad Namouni Biography and Net Worth

Insider of Blueprint Medicines

Fouad brings more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Prior to joining Blueprint Medicines, Fouad served in leadership roles at Bristol-Myers Squibb (BMS) since 1999, including as the global development lead for the company’s practice-changing cancer immunotherapy franchise. Most recently, he served as Senior Vice President and Head of Oncology Development from August 2016 to April 2020, with responsibility for driving product development plans from early-stage clinical development through commercialization across a portfolio of nearly 30 drug candidates. Previously, he served as Head of Global Medical Affairs overseeing 1,700 employees worldwide from September 2015 to September 2017, and he served as Head of Development at BMS for Opdivo® (nivolumab) and Yervoy® (ipilimumab), immunotherapy medications used in the treatment of cancer, from January 2011 to September 2015. Prior to that, he held roles of increasing responsibility within BMS. Fouad has served as a member of the board of directors of Aprea Therapeutics Inc. since June 2020. He holds an M.D. from the University of Annaba Medical School in Algeria, and a Pediatrics degree from Université Rene Descartes in Paris, France. In addition, he received a Pediatric Oncology and Hematology degree and an M.S. in clinical and experimental pharmacology from Université Paris-Sud in France.

What is Fouad Namouni's net worth?: The estimated net worth of Fouad Namouni is at least $5.73 million as of October 4th, 2023. Dr. Namouni owns 62,080 shares of Blueprint Medicines stock worth more than $5,727,501 as of April 25th. This net worth estimate does not reflect any other investments that Dr. Namouni may own. Additionally, Dr. Namouni receives an annual salary of $916,400.00 as Insider at Blueprint Medicines. Learn More about Fouad Namouni's net worth.
How old is Fouad Namouni?: Dr. Namouni is currently 55 years old. There are 8 older executives and no younger executives at Blueprint Medicines. The oldest executive at Blueprint Medicines is Dr. Christopher K. Murray Ph.D., Senior VP of Technical Operations and Chief Technical Operations & Quality Officer, who is 60 years old. Learn More on Fouad Namouni's age.
What is Fouad Namouni's salary?: As the Insider of Blueprint Medicines Co., Dr. Namouni earns $916,400.00 per year. The highest earning executive at Blueprint Medicines is Ms. Kathryn Haviland, President, CEO & Director, who commands a salary of $1,170,000.00 per year. Learn More on Fouad Namouni's salary.
How do I contact Fouad Namouni?: The corporate mailing address for Dr. Namouni and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on Fouad Namouni's contact information.
Has Fouad Namouni been buying or selling shares of Blueprint Medicines?: Fouad Namouni has not been actively trading shares of Blueprint Medicines in the last ninety days. Most recently, Fouad Namouni sold 3,769 shares of the business's stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $48.06, for a transaction totalling $181,138.14. Following the completion of the sale, the insider now directly owns 62,080 shares of the company's stock, valued at $2,983,564.80. Learn More on Fouad Namouni's trading history.
Who are Blueprint Medicines' active insiders?: Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (COO), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?: In the last twelve months, insiders at the biotechnology company sold shares 24 times. They sold a total of 172,543 shares worth more than $13,714,414.59. The most recent insider tranaction occured on March, 28th when CFO Michael Landsittel sold 5,000 shares worth more than $475,000.00. Insiders at Blueprint Medicines own 3.9% of the company. Learn More about insider trades at Blueprint Medicines.
Information on this page was last updated on 3/28/2024.

Fouad Namouni Insider Trading History at Blueprint Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/4/2023	Sell	3,769	$48.06	$181,138.14	62,080
10/4/2022	Sell	3,477	$67.30	$234,002.10	52,797
10/5/2021	Sell	3,241	$98.18	$318,201.38

Fouad Namouni Buying and Selling Activity at Blueprint Medicines

Blueprint Medicines Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $92.26

$90.43

$93.74

50 Day Range

MA: $90.67

$85.18

$99.79

2 Week Range

Now: $92.26

$43.89

$101.00

Volume

588,540 shs

Average Volume

764,526 shs

Market Capitalization

$5.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Fouad Namouni Biography and Net Worth

What is Fouad Namouni's net worth?

How old is Fouad Namouni?

What is Fouad Namouni's salary?

How do I contact Fouad Namouni?

Has Fouad Namouni been buying or selling shares of Blueprint Medicines?

Who are Blueprint Medicines' active insiders?

Are insiders buying or selling shares of Blueprint Medicines?